CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA
CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA

CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA

The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.

DSIJ Intelligence-1 Article rating: 5.0

The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP

Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg.

DSIJ Intelligence-1 Article rating: 5.0

The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.

Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd
Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd

Pharma Company Enters Into Share Purchase Agreement and Power Supply Agreement with Torrent Urja 19 Pvt Ltd

The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.

DSIJ Intelligence-1 Article rating: 4.5

The company has a market cap of over Rs 13,000 crore and the stock is up 45 per cent from its 52-week low of Rs 743.60 per share.

46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why
46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why

46 Per Cent Returns From 52-Week Low: Pharma Stock Under Rs 75, Hit 10 Per Cent Upper Circuit; Here’s Why

The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.

DSIJ Intelligence-1 Article rating: 5.0

The company has a market cap of over Rs 400 crore and the stock is up by 46 per cent from its 52-week low of Rs 50.42 per share.

Pharma Giant Expands with Strategic Acquisition in Singapore
Pharma Giant Expands with Strategic Acquisition in Singapore

Pharma Giant Expands with Strategic Acquisition in Singapore

The company has a strong presence in regulated markets such as the United States and Europe and is a leading producer of niche generic formulations.

DSIJ Intelligence-1 Article rating: 4.0

The company has been actively expanding its product pipeline, with over 70 commercialized products and a healthy pipeline of 100+ approved products.

Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19
Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19

Rakesh Jhunjhunwala’s portfolio gains 19,19,23,388.25 in just 1 day: Multibagger pharma stock locked in upper circuit on March 19

The stock gave multibagger returns of 160 per cent in just 1 year whereas BSE Sensex Index is up by 5 per cent.

DSIJ Intelligence-1 Article rating: 3.6

The stock’s 52-week high is Rs 1,678.60 per share while its 52-week low is Rs 489.20 per share.

RSS
1234567

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR